Identification and Management of Acute Kidney Injury in Select Pediatric

​Populations
​
Matthew Buchfellner
Abstract
There is no curative pharmacologic treatment for acute kidney injury (AKI). However, these episodes of AKI can be frequent in critically ill pediatric patients admitted to the intensive care unit. The classification of pediatric AKI is based upon increased serum creatinine levels or decreases in urine output. Pediatric AKI can be classified depending on what criteria and which guideline for treatment is used. Optimization of volume status and blood pressure, avoidance of nephrotoxins, and nutritional support are critical for early stage or patients at high risk for developing AKI to decrease mortality and improve long term outcomes in selected pediatric patient populations such as neonates, young adults, and transplant patients.

Full Text
Vol 6 Article 1
File Size: 237 kb
File Type: pdf
Download File

Notice and Disclaimer

Medicine is an ever-changing science.  As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required.  The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication.  However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work.    Readers are encouraged to confirm the information contained herein with other sources.   For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.

Subscribe to ARxCH